Sanofi has recently announced its decision (in agreement with the Department of Health and Social Care and the Medicines and Healthcare products Regulatory Agency) to discontinue three Insuman® (recombinant human insulin) products across the UK in spring and summer of this year.
The company said the discontinuations were due to limited capacity at the manufacturing site, not due to any safety issue, therefore Insuman® currently available is safe and can continue to be used.
Insuman products to be discontinued are:
- Insuman® Comb 15 100 IU/mL – suspension for injection in a cartridge – Subcutaneous use. Expected End of Supply –June 2020.
- Insuman® Basal 100 IU/mL – suspension for injection in a vial – Subcutaneous use. Expected End of Supply – May 2020.
- Insuman® Comb 25 100 IU/mL- suspension for injection in a vial – Subcutaneous use. Expected End of Supply – June 2020.
What to do if this affects you
If you’re currently treated with Insuman® vials and cartridges and this will affect you, we recommend that you discuss with your diabetes healthcare team a suitable alternative insulin preparation which would best suit your individual needs.
Any questions?
For any questions regarding this particular discontinuation, you can contact Sanofi’s Medical Information helpline on 0845 372 7101 or uk-medicalinformation@sanofi.com.
For additional support, you can also contact our helpline.
